Immune adjuvant – Japan (Patent No. 5242855)
Immune adjuvant – Japan (Patent No. 5242855) Patent Details Country of RegistrationJapan Patent No.No. 5242855Registration DateApril 12, 2013 Aureobasidium (black yeast) culture medium (hereafter referred to as “Aureo culture medium”) was tested as an “adjuvant” substance to further...
Immune adjuvant – Japan (Patent No. 5242855)
| Country of Registration | Japan |
|---|---|
| Patent No. | No. 5242855 |
| Registration Date | April 12, 2013 |
Aureobasidium (black yeast) culture medium (hereafter referred to as “Aureo culture medium”) was tested as an “adjuvant” substance to further enhance the efficacy of the intranasal vaccine.
The group that received the intranasal vaccine alone showed higher antibody titers for both IgA and IgG than the group that received the intranasal vaccine in combination with the Aureo culture medium.
These results indicate that Aureo culture medium has an adjuvant effect for intranasal vaccines.
Adjuvant : A substance that aids or enhances the effect of a vaccine.
IgA : Antibody that exists in large quantities in mucous membranes
IgG : Antibody that exists in large quantities in the serum
Continue with the research library
Explore source fields, DOI/PMID notes, limitations, and related beta glucan references.